CVS Health posts strong Q4 revenue, raises full-year guidance

CVS Health Corp (NYSE:CVS) connected Tuesday reported stronger-than-expected fourth-quarter gross and adjusted earnings, driven by maturation crossed its pharmacy, wellness services, and security businesses.

The US pharmacy concatenation and wellness insurer said fourth-quarter gross roseate 8.2% to $105.7 billion, topping analysts’ expectations of $103.6 billion.

Adjusted net per stock (EPS) came successful astatine $1.09, supra the $1.00 forecast. GAAP nett income for the 4th was $2.923 billion, with operating income of $2.112 billion.

Full-year 2025 gross climbed 7.8% to a grounds $402.1 billion. Adjusted EPS for the twelvemonth was $6.75, portion GAAP diluted EPS was $1.39. The institution generated $10.6 cardinal successful currency travel from operations for the year.

Operationally, CVS said its pharmacy conception completed the modulation to cost-based reimbursement crossed commercial, Medicare, and Medicaid businesses. Health insurer Aetna approved much than 95% of each eligible anterior authorizations wrong 24 hours, with galore processed instantaneously. CVS Caremark besides reported beardown lawsuit retention and wins heading into 2026.

Looking ahead, CVS confirmed its 2026 full-year guidance for adjusted EPS astatine $7 to $7.20, somewhat supra analysts’ estimation of $7.17. GAAP EPS guidance is acceptable astatine $5.94 to $6.14. The institution updated its currency travel from operations guidance to astatine slightest $9 billion, down from the erstwhile $10 billion.

“Our 4th fourth and full-year results show the advancement we are making successful transforming the wellness attraction acquisition with our unsocial postulation of businesses,” CVS CEO David Joyner said. “From lowering cause prices, to improving navigation of wellness care, to being the beforehand doorway of attraction crossed our country, we are good positioned to execute our ambition to beryllium the astir trusted wellness attraction institution successful America.”

Shares roseate 2.6% successful aboriginal trading.